Table 1. Results of non-infectious posterior uveitis following two weeks of dexamethasone intravitreal administration. Change in VA (ETDRS letters) and foveal thickness (CMT µm).

Patient	Eyes	Age	Sex	Diagnosis	Systemic immuno suppresion prior to Ozurdex®	Baseline VA	Post treatment VA	Baseline CMT (µm)	Post treatment CMT (µm)	Frequency of Ozurdex® treatment	Duration of follow up (mo)
No.1	OS	52	F	Bilateral panuveitis	Y	63	76	696	365	Once	18
No.2	OD	49	M	Birdshot chorioretinopathy	N	78	83	621	319	Twice	16
No.2	OS	49	M	Birdshot chorioretinopathy	N	72	82	463	349	Once	16
No.3	OD	51	F	Idiopathic Intermediate uveitis	Y	43	49	675	224	Once	14
No.3	OS	51	F	Idiopathic Intermediate uveitis	Y	63	78	446	333	Once	14
No.4	OS	30	F	Panuveitis	N	61	72	496	230	Once	12

VA: Visual acuity; CMT: Central macular thickness.